| PEDIATRICS RELATED ARTICLES |
| Title | Volume/Issue | Page |
| Emanuel Butt Paste |
Vol. 13 No. 5 |
431 |
| Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding |
Vol. 13 No. 4 |
314 |
| Compounding Naltrexone for the Treatment of Autism |
Vol. 13 No. 4 |
296 |
| Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report |
Vol. 13 No. 3 |
220 |
| Compounding for Pediatric Patients: Case Reports and Formulations |
Vol. 13 No. 1 |
6 |
| Evaluation of Dosage Form Information Provided in Pediatric Drug Trial Reports |
Vol. 13 No. 1 |
14 |
| Calculations |
Vol. 13 No. 1 |
63 |
| Acetaminophen, Pseudoephedrine Hydrochloride, and Chlorpheniramine Maleate Powder Packets |
Vol. 13 No. 1 |
64 |
| Amphotericin B, Chloramphenicol Palmitate, Hydrocortisone, and Sulfanilamide Otic Powder |
Vol. 13 No. 1 |
65 |
| Diaper Rash Cream with Miconazole |
Vol. 13 No. 1 |
68 |
| Diphenhydramine Hydrochloride 25-mg Gelatin Troches |
Vol. 13 No. 1 |
69 |
| Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada |
Vol. 12 No. 4 |
365 |
| Benzyl Benzoate Lotion |
Vol. 12 No. 3 |
261 |
| Valsartan 4-mg/mL Oral Liquid |
Vol. 12 No. 3 |
269 |
| Trimethoprim 10-mg/mL Oral Suspension |
Vol. 12 No. 1 |
73 |
| Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 |
Vol. 11 No. 3 |
220 |
| Methylphenidate 1-mg/mL Oral Liquid |
Vol. 11 No. 3 |
249 |
| Challenges of Compounding for Patients on the Ketogenic Diet |
Vol. 11 No. 2 |
116 |
| Ranitidine Hydrochloride 15-mg/mL Oral Liquid |
Vol. 11 No. 2 |
161 |
| Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development—Pediatric Formulations Initiative, Part 1 |
Vol. 11 No. 1 |
5 |
| Principles of Pediatric Palliative Care and Pain Control |
Vol. 11 No. 1 |
10 |
| Pediatric Oral Formulations: A Continual Challenge |
Vol. 11 No. 1 |
17 |
| Sevelamer Suspension in Children with End-Stage Renal Disease |
Vol. 11 No. 1 |
20 |
| Case Report: Cocktail Dosing in a Premature Infant with a History of Cholestasis |
Vol. 11 No. 1 |
26 |
| Case Report: Treatment of Labial Adhesions in a Child |
Vol. 11 No. 1 |
27 |
| Calculations |
Vol. 11 No. 1 |
68 |
| Caffeine Citrate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
69 |
| Carbidopa 1.25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
70 |
| Clonidine Hydrochloride 0.1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
71 |
| Methyldopa 25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
75 |
| Metolazone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
76 |
| Prednisone 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
77 |
| Prednisolone Sodium Phosphate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
78 |
| Nitrazepam 1-mg/mL Oral Liquid |
Vol. 10 No. 5 |
388 |
| Oral Rehydration Salts (World Health Organization/United Nations Children's Fund) |
Vol. 10 No. 5 |
390 |
| Adderall 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
299 |
| Lisinopril 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
302 |
| Nifedipine 4-mg/mL Oral Liquid |
Vol. 10 No. 4 |
303 |
| Propranolol Hydrochloride 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
304 |
| Propylthiouracil 5-mg/mL Oral Liquid |
Vol. 10 No. 1 |
67 |
| Prescription: Pediatric Formulation Initiatives |
Vol. 9 No. 6 |
410 |
| Unlocking Autism: Is Compounding the Key? |
Vol. 9 No. 6 |
413 |
| Compounding for a Pediatric Hospital |
Vol. 9 No. 6 |
423 |
| Wiping Out Diaper Rash |
Vol. 9 No. 6 |
433 |
| Pediatric Oral Liquid Preparations |
Vol. 9 No. 6 |
437 |
| Basics of Compounding for Pediatric Patients: Commonly Prescribed Oral Liquid Formulations, Vehicles, and Stock Solutions |
Vol. 9 No. 6 |
456 |
| PostScription: Compounding Pharmacies and the Successful Treatment of Autism |
Vol. 9 No. 6 |
487 |
| Calculations |
Vol. 9 No. 1 |
57 |
| Stability of an Extemporaneously Compounded Propylthiouracil Suspension |
Vol. 9 No. 1 |
82 |
| A Need for Propylene Glycol-Free Ascorbic Acid Oral Liquid |
Vol. 8 No. 6 |
458 |
| Domperidone in Lactation: Use as a Galactagogue |
Vol. 8 No. 5 |
329 |
| Head to Toe Solutions: A Quick Review of Current Therapies |
Vol. 8 No. 5 |
345 |
| Book and Literature Reviews |
Vol. 8 No. 4 |
244 |
| Gag Tablet Lollipops |
Vol. 8 No. 3 |
184 |
| Amiodarone HCl 5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
214 |
| Atenolol 2-mg/mL Oral Liquid |
Vol. 8 No. 3 |
215 |
| Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
218 |
| Flucytosine 10-mg/mL Oral Liquid |
Vol. 8 No. 2 |
134 |
| Griseofulvin 25-mg/mL Oral Liquid |
Vol. 8 No. 2 |
135 |
| Stomatitis Mouthwash |
Vol. 8 No. 2 |
140 |
| Tacrolimus 0.5-mg/mL Oral Liquid |
Vol. 8 No. 2 |
141 |
| Tiagabine 1-mg/mL Oral Liquid |
Vol. 8 No. 2 |
142 |
| Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
| Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension |
Vol. 7 No. 6 |
485 |
| Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
| Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
| Ursodiol 150-mg Capsules |
Vol. 7 No. 5 |
382 |
| Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
| Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
| Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
| Pediatric Dermatitis |
Vol. 6 No. 6 |
419 |
| Excerpts from and Reviews of Current Published Literature: Pediatric Medications |
Vol. 6 No. 6 |
423 |
| Book Reviews: Compounding for Pediatric Patients |
Vol. 6 No. 6 |
424 |
| Caffeine and Sodium Benzoate 250-mg/mL Injection |
Vol. 6 No. 6 |
449 |
| Dimenhydrinate 50-mg/mL Injection |
Vol. 6 No. 6 |
451 |
| Erythromycin 400-mg/mL and Rifampin 50-mg/mL Oral Liquid |
Vol. 6 No. 5 |
367 |
| Topical Secretin for the Treatment of Autism |
Vol. 5 No. 6 |
436 |
| Basics of Compounding: Suspensions |
Vol. 5 No. 4 |
294 |
| Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
| Sugar-Free Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
| Spironolactone Oral Suspension 2-mg/mL |
Vol. 5 No. 4 |
297 |
| Progesterone Oral Suspension 40-mg/mL |
Vol. 5 No. 4 |
297 |
| Xanthan Gum Oral Suspension Vehicle 0.3% |
Vol. 5 No. 4 |
297 |
| Pediatric Preoperative Cocktail Injection |
Vol. 5 No. 4 |
306 |
| Basics of Compounding Emulsions, Part 2, The |
Vol. 5 No. 3 |
198 |
| Basics of Compounding Emulsions, Part 1, The |
Vol. 5 No. 2 |
120 |
| Pediatric Compounding: Coloring Outside the Lines |
Vol. 5 No. 1 |
6 |
| Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients |
Vol. 5 No. 1 |
9 |
| Flavoring: Compounding a Treat |
Vol. 5 No. 1 |
13 |
| Autism in Children |
Vol. 5 No. 1 |
18 |
| Methylphenidate in the Treatment of Attention Deficit Disorders |
Vol. 5 No. 1 |
21 |
| Pediatric Miscellany: Excerpts from and Reviews of Current Published Literature, A |
Vol. 5 No. 1 |
23 |
| Compounding in History: Pediatric Considerations |
Vol. 5 No. 1 |
30 |
| Electrolyte and Rehydration Powder for Solution-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
| Cholestyramine 6.5% Ointment |
Vol. 5 No. 1 |
42 |
| Ivermectin 0.8% Creme Rinse |
Vol. 5 No. 1 |
43 |
| Lidocaine HCl 4%-Epinephrine HCl 0.05%-Tetracaine HCl 0.5% Topical Gel |
Vol. 5 No. 1 |
44 |
| Lorazepam 1-mg Chewable Gummy Gels |
Vol. 5 No. 1 |
45 |
| Metronidazole Benzoate 400-mg/5-mL Oral Suspension |
Vol. 5 No. 1 |
46 |
| Natural Head Lice Repellant Spray |
Vol. 5 No. 1 |
48 |
| Niacinamide 4% Acne Gel |
Vol. 5 No. 1 |
49 |
| Promethazine HCl 50-mg/mL in PLO Gel |
Vol. 5 No. 1 |
51 |
| Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations |
Vol. 4 No. 4 |
289 |
| Ondansetron HCl 8-mg/mL in PLO |
Vol. 4 No. 4 |
305 |
| Compounding Ear, Nose and Throat Preparations |
Vol. 4 No. 3 |
164 |
| Xylitol in the Prevention of Otitis Media |
Vol. 4 No. 3 |
171 |
| Sildenafil 0.2% Otic Drops |
Vol. 4 No. 3 |
175 |
| Amphotericin B 100-mg Troches |
Vol. 4 No. 3 |
208 |
| Nystatin 250,000-Unit and/or Tetracaine HCl 0.025% Popsicles |
Vol. 4 No. 3 |
214 |
| Basics of Compounding: Compounding Solutions |
Vol. 4 No. 2 |
122 |
| Sugar-Free Suspension Structured Vehicle, USP |
Vol. 4 No. 2 |
136 |
| The Basics of Compounding: Compounding Hard, Soft and Chewable Troches/Lozenges/Drops |
Vol. 3 No. 6 |
461 |
| Linguet Base (Soft Lozenge) |
Vol. 3 No. 6 |
462 |
| Sorbitol Based Hard Lozenges |
Vol. 3 No. 6 |
462 |
| Sucrose Based Hard Lozenges |
Vol. 3 No. 6 |
462 |
| Polyethylene Glycol (PEG) Troches (Soft Lozenges) |
Vol. 3 No. 6 |
463 |
| Polyethylene Glycol (PEG) Troches with Suspending Agent (Soft Lozenges) |
Vol. 3 No. 6 |
463 |
| Chewable Lozenges |
Vol. 3 No. 6 |
464 |
| Methotrexate 2.5-mg/5-mL Oral Liquid |
Vol. 3 No. 6 |
474 |
| Extemporaneous Formulations in Pediatric Patients |
Vol. 3 No. 4 |
274 |
| Analysis of Extemporaneous Alprostadil Formulations |
Vol. 3 No. 2 |
148 |
| Oral Ulceration Mouthwash |
Vol. 3 No. 1 |
10 |
| Alternatives for the Lactose-Intolerant Patient |
Vol. 2 No. 6 |
412 |
| Pediatric Central Parenteral Nutrition Solution |
Vol. 2 No. 5 |
368 |
| Pediatric Central Parenteral Nutrition Solution with Heparin |
Vol. 2 No. 5 |
369 |
| Pediatric Peripheral Parenteral Nutrition Solution |
Vol. 2 No. 5 |
370 |
| Malathion Topical Lotion: Therapy for Resistant Head Lice |
Vol. 2 No. 4 |
268 |
| Compatibility and Stability of Ranitidine Hydrochloride with Six Cephalosporins During Simulated Y-Site Administration |
Vol. 2 No. 4 |
318 |
| Tetracaine HCl 1%, Epinephrine HCl 0.025% and Cocaine HCl 4% Topical Solution and Gel |
Vol. 2 No. 2 |
159 |
| Vehicles for Compounding Oral Liquids: Some Practical Considerations |
Vol. 2 No. 2 |
160 |
| Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane |
Vol. 2 No. 1 |
83 |
| Ketoconazole 20-mg/mL Oral Liquid |
Vol. 1 No. 6 |
414 |
| Baclofen 10-mg/mL Oral Liquid |
Vol. 1 No. 5 |
321 |
| Captopril 0.75-mg/mL Oral Liquid |
Vol. 1 No. 5 |
322 |
| Diltiazem HCl 12-mg/mL Oral Suspension |
Vol. 1 No. 5 |
323 |
| Stability of Bethanechol Chloride Oral Liquid Dosage Forms |
Vol. 1 No. 4 |
278 |
| Allopurinol 20-mg/mL Oral Liquid |
Vol. 1 No. 3 |
174 |
| Dipyridamole 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
176 |
| Labetalol HCl 40-mg/mL Oral Liquid |
Vol. 1 No. 3 |
179 |
| Metoprolol Tartrate 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
180 |
| Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid |
Vol. 1 No. 3 |
183 |
| Spironolactone 25-mg/mL Oral Liquid |
Vol. 1 No. 3 |
184 |
| Verapamil HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 3 |
188 |
| Formulation Development and Stability of Spironolactone Suspension, The |
Vol. 1 No. 3 |
195 |
| Formulation Development and Stability of Metronidazole Suspension, The |
Vol. 1 No. 3 |
200 |
| Metronidazole 15-mg/mL Suspension |
Vol. 1 No. 3 |
202 |
| Compounding for the Pediatric Patient |
Vol. 1 No. 2 |
84 |
| Attention Deficit Hyperactivity Disorder |
Vol. 1 No. 2 |
87 |
| Flavors and Flavoring |
Vol. 1 No. 2 |
90 |
| Compounded Suppositories and Pharmaceutical Care |
Vol. 1 No. 2 |
93 |
| Acetazolamide 25-mg/mL Oral Liquid |
Vol. 1 No. 2 |
101 |
| Azathioprine 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
102 |
| Flecainide Acetate 20-mg/mL Oral Liquid |
Vol. 1 No. 2 |
103 |
| Methylcellulose 1% to 5% Solutions |
Vol. 1 No. 2 |
104 |
| Methylcellulose Oral-Liquid Vehicles |
Vol. 1 No. 2 |
105 |
| Pediatric Chewable Gummy Gel Base |
Vol. 1 No. 2 |
106 |
| Pediatric Chocolate Troche Base |
Vol. 1 No. 2 |
106 |
| Pediatric Chewable Gummy Gels |
Vol. 1 No. 2 |
107 |
| Pediatric Chocolate Troche |
Vol. 1 No. 2 |
108 |
| Nystatin Popsicles |
Vol. 1 No. 2 |
109 |
| Procainamide HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
110 |
| Syrup NF |
Vol. 1 No. 2 |
111 |
| Tetracaine 20-mg Lollipops |
Vol. 1 No. 2 |
112 |
| Tetracycline Compound Troche |
Vol. 1 No. 2 |
113 |
| Xanthan Gum Suspension Vehicle (0.2% to 0.5%) |
Vol. 1 No. 2 |
114 |
| Omeprazole (Prilosec) in the Atypical Patient, Administration of |
Vol. 1 No. 1 |
13 |
| HDDM Hard Troche |
Vol. 1 No. 1 |
29 |
| HDDM Soft Troche |
Vol. 1 No. 1 |
30 |
| HDDM Sugar Troche |
Vol. 1 No. 1 |
30 |
| Metoclophen Nausea Suppositories |
Vol. 1 No. 1 |
31 |
| Metoclophen-Modified Nausea Suppositories |
Vol. 1 No. 1 |
31 |
| Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup compounded from commercial tablets |
Vol. 1 No. 1 |
60 |
| GERIATRICS RELATED ARTICLES |
| Title | Volume/Issue | Page |
| PreScription: Geriatric Compounding: An Opportunity for Pharmacists |
Vol. 13 No. 6 |
492 |
| Low Testosterone in Older Men: A Discussion and Review of Literature on Health Consequences of Hypogonadism in the Aging Male |
Vol. 13 No. 6 |
494 |
| Compliance to Treatment in Elderly Dysphagic Patients: Potential Benefits of Alternate Dosage Forms |
Vol. 13 No. 6 |
498 |
| Marketing the Geriatric Patient |
Vol. 13 No. 6 |
538 |
| Calculations |
Vol. 13 No. 6 |
545 |
| Selegiline Hydrochloride 1-mg/0.05-mL Oral Suspension in Oil |
Vol. 13 No. 4 |
340 |
| Arthritis Epidemiology Impacts Pharmacists |
Vol. 12 No. 6 |
476 |
| Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration |
Vol. 12 No. 1 |
8 |
| Calculations |
Vol. 11 No. 1 |
68 |
| Carbidopa 1.25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
70 |
| Clonidine Hydrochloride 0.1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
71 |
| Methyldopa 25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
75 |
| Metolazone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
76 |
| Propranolol Hydrochloride 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
304 |
| Stability of an Extemporaneously Compounded Propylthiouracil Suspension |
Vol. 9 No. 1 |
82 |
| Book and Literature Reviews |
Vol. 8 No. 4 |
244 |
| Case Report: Wound Care of a Diabetic Foot Ulcer |
Vol. 8 No. 4 |
265 |
| Current Topical Treatments in Wound Healing - Part 1 |
Vol. 8 No. 4 |
269 |
| Atropine 1-mg Gelatin Troches |
Vol. 8 No. 3 |
184 |
| Clonidine HCl 0.2%/Gabapentin 6%/Ketamine HCl 10% in Pluronic Lecithin Organogel (PLO) |
Vol. 8 No. 3 |
185 |
| Pain Management in the Elderly |
Vol. 8 No. 3 |
187 |
| Amiodarone HCl 5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
214 |
| Atenolol 2-mg/mL Oral Liquid |
Vol. 8 No. 3 |
215 |
| Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
218 |
| Flucytosine 10-mg/mL Oral Liquid |
Vol. 8 No. 2 |
134 |
| Griseofulvin 25-mg/mL Oral Liquid |
Vol. 8 No. 2 |
135 |
| Stomatitis Mouthwash |
Vol. 8 No. 2 |
140 |
| Tacrolimus 0.5-mg/mL Oral Liquid |
Vol. 8 No. 2 |
141 |
| Tiagabine 1-mg/mL Oral Liquid |
Vol. 8 No. 2 |
142 |
| Extemporaneous Formulation and Stability Testing of Mexiletine HCl Solution |
Vol. 8 No. 2 |
147 |
| Ergoloid Mesylate 1-mg/mL Oral Liquid |
Vol. 7 No. 6 |
470 |
| Perphenazine 2.5-mg/5-mL Syrup |
Vol. 7 No. 6 |
473 |
| Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
| Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
| Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
| Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
| Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
| Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
| Levofloxacin 250-mg/5mL Oral Liquid |
Vol. 7 No. 1 |
60 |
| Ofloxacin 250-mg/5-mL Oral Liquid |
Vol. 7 No. 1 |
60 |
| Erythromycin 400-mg/mL and Rifampin 50-mg/mL Oral Liquid |
Vol. 6 No. 5 |
367 |
| Mild Laxative |
Vol. 6 No. 3 |
185 |
| Liver Pills for All Obstructions of the Liver, Gall Ducts, and Bowel |
Vol. 6 No. 3 |
185 |
| Compounding for Geriatrics Patients |
Vol. 6 No. 3 |
168 |
| Estrogen Replacement Therapy in the Treatment of Alzheimer's Disease |
Vol. 6 No. 3 |
171 |
| Book Reviews: Wellness, Nutrition and Geriatrics |
Vol. 6 No. 3 |
180 |
| Carbidopa 2-mg/mL and Levodopa 250-mg/mL Oral Suspension |
Vol. 6 No. 3 |
202 |
| Bioidentical Hormones in the Treatment of Osteoporosis |
Vol. 5 No. 5 |
339 |
| Basics of Compounding: Suspensions |
Vol. 5 No. 4 |
294 |
| Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
| Sugar-Free Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
| Spironolactone Oral Suspension 2-mg/mL |
Vol. 5 No. 4 |
297 |
| Progesterone Oral Suspension 40-mg/mL |
Vol. 5 No. 4 |
297 |
| Xanthan Gum Oral Suspension Vehicle 0.3% |
Vol. 5 No. 4 |
297 |
| Basics of Compounding Emulsions, Part 2, The |
Vol. 5 No. 3 |
198 |
| Basics of Compounding Emulsions, Part 1, The |
Vol. 5 No. 2 |
120 |
| Electrolyte and Rehydration Powder for Solution-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
| Milk of Magnesia Concentrate, Unflavored |
Vol. 5 No. 1 |
47 |
| Nicotinamide-Adenine Dinucleotide (NADH) in Parkinson's Disease and Alzheimer's Disease |
Vol. 4 No. 4 |
276 |
| Amphotericin B 100-mg Troches |
Vol. 4 No. 3 |
208 |
| Saliva Substitute for Dry Mouth/Throat |
Vol. 4 No. 3 |
215 |
| Basics of Compounding: Compounding Solutions |
Vol. 4 No. 2 |
122 |
| Osteoarthritis: Other Options |
Vol. 3 No. 6 |
433 |
| Methotrexate 2.5-mg/5-mL Oral Liquid |
Vol. 3 No. 6 |
474 |
| Alternatives for the Lactose-Intolerant Patient |
Vol. 2 No. 6 |
412 |
| Treatment of Skin Aging with Topical Estrogens |
Vol. 2 No. 4 |
270 |
| Stability of Ciprofloxacin in Extemporaneous Oral Liquid Dosage Form |
Vol. 2 No. 4 |
314 |
| Vehicles for Compounding Oral Liquids: Some Practical Considerations |
Vol. 2 No. 2 |
160 |
| Estrogen in the Treatment and Prevention of Alzheimer's Disease |
Vol. 2 No. 1 |
24 |
| Ketoconazole 20-mg/mL Oral Liquid |
Vol. 1 No. 6 |
414 |
| Baclofen 10-mg/mL Oral Liquid |
Vol. 1 No. 5 |
321 |
| Captopril 0.75-mg/mL Oral Liquid |
Vol. 1 No. 5 |
322 |
| Diltiazem HCl 12-mg/mL Oral Suspension |
Vol. 1 No. 5 |
323 |
| Metolazone 1-mg/mL Oral Suspension |
Vol. 1 No. 5 |
329 |
| Stability of Bethanechol Chloride Oral Liquid Dosage Forms |
Vol. 1 No. 4 |
278 |
| Creative Compounding for the Geriatric Patient |
Vol. 1 No. 3 |
147 |
| Drug Products and Drug Packaging for the Elderly |
Vol. 1 No. 3 |
150 |
| Common Diseases of the Elderly |
Vol. 1 No. 3 |
152 |
| Allopurinol 20-mg/mL Oral Liquid |
Vol. 1 No. 3 |
174 |
| Dipyridamole 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
176 |
| Labetalol HCl 40-mg/mL Oral Liquid |
Vol. 1 No. 3 |
179 |
| Metoprolol Tartrate 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
180 |
| Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid |
Vol. 1 No. 3 |
183 |
| Spironolactone 25-mg/mL Oral Liquid |
Vol. 1 No. 3 |
184 |
| Verapamil HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 3 |
188 |
| Metronidazole 15-mg/mL Suspension |
Vol. 1 No. 3 |
202 |
| Acetazolamide 25-mg/mL Oral Liquid |
Vol. 1 No. 2 |
101 |
| Azathioprine 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
102 |
| Flecainide Acetate 20-mg/mL Oral Liquid |
Vol. 1 No. 2 |
103 |
| Methylcellulose 1% to 5% Solutions |
Vol. 1 No. 2 |
104 |
| Methylcellulose Oral-Liquid Vehicles |
Vol. 1 No. 2 |
105 |
| Procainamide HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
110 |
| Syrup NF |
Vol. 1 No. 2 |
111 |
| Tetracaine 20-mg Lollipops |
Vol. 1 No. 2 |
112 |
| Tetracycline Compound Troche |
Vol. 1 No. 2 |
113 |
| Xanthan Gum Suspension Vehicle (0.2% to 0.5%) |
Vol. 1 No. 2 |
114 |
| Stability of Allopurinol Suspension Compounded from Tablets |
Vol. 1 No. 2 |
128 |
| Hospice Care and the Pharmacist |
Vol. 1 No. 1 |
11 |
| Omeprazole (Prilosec) in the Atypical Patient, Administration of |
Vol. 1 No. 1 |
13 |
| Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup compounded from commercial tablets |
Vol. 1 No. 1 |
60 |